Stockhead TV
Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Osteopore is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery use.
Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Osteopore makes first shipment to Colombia, the first of many Latin American markets it will pursue
Health & Biotech
Stock Insiders: Bone healing company Osteopore is regenerating bones with 3D-printed scaffold system
Health & Biotech
Grey matters: Osteopore shares rise on Singular opportunity to improve cranial implants through AI
Health & Biotech
ASX Health Stocks: US FDA approval could expand EBR Systems’ addressable market by $400m
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
Osteopore delivers strong sequential quarterly sales growth, expects further traction as pandemic restrictions loosen
Health & Biotech
Osteopore’s new Singapore deal takes a big bite out of next-gen dental implant tech
News
ASX Small Cap Lunch Wrap: Who’s overwhelmed by sheer numbers today?
Health & Biotech
ASX Health Stocks: Arovella and Imugene break away from the pack on major announcements
Health & Biotech
Mesoblast has long been the one poster child for stem cell therapy. Now Cynata and other ASX stocks have emerged
Health & Biotech
Osteopore granted key regulatory approval in Hong Kong
Health & Biotech
Osteopore granted patent in China, makes a move into the big Chinese market
Health & Biotech
Osteopore Ltd books improvement in gross margins as it eyes a strong pipeline of post-COVID sales opportunities
Health & Biotech
Singular Health secures funding from CSIRO to develop AI-based cranial implants with Osteopore
Health & Biotech
ASX Health Stocks: Alterity moves to Phase 2 on cancer drug, Race Oncology secures 6th US patent
Escrow Watch
Escrow Watch: Who’s undertaking a release of shares in escrow in September?
Health & Biotech